A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
Tóm tắt
Từ khóa
Tài liệu tham khảo
Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136
Dvorak, 2002, Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, J Clin Oncol, 20, 4368, 10.1200/JCO.2002.10.088
Strizzi, 2001, Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma, J Pathol, 193, 468, 10.1002/path.824
Ohta, 1999, VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours, Br J Cancer, 81, 54, 10.1038/sj.bjc.6690650
Takahashi, 1999, VEGF activates protein kinase C-dependent, but ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells, Oncogene, 18, 2221, 10.1038/sj.onc.1202527
Versnel, 1991, Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors, Oncogene, 6, 2005
Whitson, 2006, Molecular pathways in malignant pleural mesothelioma, Cancer Lett, 239, 183, 10.1016/j.canlet.2005.08.010
Klominek, 1998, Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction, Clin Exp Metastasis, 16, 529, 10.1023/A:1006542301794
Wilhelm, 2004, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, 7099, 10.1158/0008-5472.CAN-04-1443
Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655
Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857
Byrne, 2004, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann Oncol, 15, 257, 10.1093/annonc/mdh059
Steele, 2000, Phase II study of vinorelbine in patients with malignant pleural mesothelioma, J Clin Oncol, 18, 3912, 10.1200/JCO.2000.18.23.3912
Kindler, 2001, Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B, Lung Cancer, 31, 311, 10.1016/S0169-5002(00)00166-5
Stebbing, 2009, The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma, Lung Cancer, 63, 94, 10.1016/j.lungcan.2008.04.001
Abou-Alfa, 2006, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 24, 4293, 10.1200/JCO.2005.01.3441
Hayat, 2007, Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program, Oncologist, 12, 20, 10.1634/theoncologist.12-1-20
Karrison, 2007, Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM), J Clin Oncol, 18s
Francart, 2009, A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials, Eur J Cancer, 45, 2304, 10.1016/j.ejca.2009.04.028
Krug, 2006, Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid, Clin Lung Cancer, 7, 257, 10.3816/CLC.2006.n.003
Tsao, 2007, Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion, Mol Cancer Ther, 6, 1962, 10.1158/1535-7163.MCT-07-0052
Jahan, 2005, Vatalanib in patients with previously untreated advanced malignant mesothelioma: preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107), Lung Cancer, 49
Baas, 2005, Thalidomide in patients with malignant pleural mesothelioma, Lung Cancer, 48, 291, 10.1016/j.lungcan.2004.10.005
Kindler, 2001, SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study, Proc Am Soc Clin Oncol, 20
Pavlakis, 2003, Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomized phase II studies, Lung cancer, 41, S11, 10.1016/S0169-5002(03)91684-9
Nowak, 2008, Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MM), J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.8063
Garland, 2009, A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma, J Clin Oncol, 27